Search Results for: Pharma: Clinical Roundup
-
Biotech Yields Another in Bumper Crop of IPOs
Earlier this month, at the American Society of Clinical Oncology annual meeting in Chicago, Onconova presented interim data from its Phase II ONTARGET study testing oral rigosertib as a single agent in transfusion-dependent, lower risk MDS patients...Intercept Pharmaceuticals Inc., of New York, commenced an underwritten public offering of about 1.7 million shares of its common stock -
Pharma: Clinic Roundup
Bristol-Myers Squibb Co., of New York, reported year two data from the AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve rheumatoid arthritis Subjects With Background Methotrexate) trial of 646 patients comparing the safety and efficacy of the subcutaneous formulation of abatacept (Orencia) vs...The study demonstrated the superiority of ozenoxacin 1 percent cream, applied topically for five days, compared to placebo on both clinical and bacteriological endpoints by end-of-therapy -
Akebia's $41M Cash Infusion Boosts Anemia Drug Work
Autifony Therapeutics Ltd., of London, said Pfizer Venture Investments, the venture capital arm of Pfizer Inc., of New York, invested £5 million (US$7.7 million) to join existing investors SV Life Sciences, Imperial Innovations plc and UCL Business plc in its Series A financing round...The financing is expected to fund the lead program to clinical proof of concept for at least one hearing disorder indication. (See BioWorld Today, Aug. 23, 2011 -
ASCO Roundup
Data from an ongoing Phase I/II study confirmed clinical evidence of the antitumor activity at multiple dose levels in patients with anaplastic lymphoma kinase-positive NSCLC, including brain metastases, and initial clinical evidence of antitumor activity in patients with EGFR receptor mutation NSCLC. (See BioWorld Today, Dec. 17, 2012...and the clinical benefit response rate was 82 percent -
Clinic Roundup
The study is being sponsored by the Alliance for Clinical Trials in Oncology, a cooperative group of the National Cancer Institute (NCI...In the trial, aldoxorubicin showed prolonged clinical activity, including partial tumor response, in two subjects with small-cell lung cancer who had failed other therapies...Promedior Inc., of Lexington, Mass., presented data from a clinical study of PRM-151 at the American Thoracic Society Conference in Philadelphia -
IPOpalooza Continues with Portola's $122M Offering
GW Pharma plc (NASDAQ:GWPH) commenced trading on May 1, pricing at $8.90, and closed at $8.88 Wednesday...Oligomerix Inc., of New York, completed a $2.8M Series B financing, which included both the issuance of new convertible preferred shares and warrants -
Pharma: Clinic Roundup
Bristol-Myers Squibb Co., of New York, and Pfizer Inc., also of New York, said results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, showing that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliqus (apixaban) compared to warfarin were consistent across subgroups defined based on levels of International Normalized Ratio control in patients with nonvalvular atrial fibrillation -
Clinic Roundup
clinical trials, for SMD and dry age-related macular degeneration (dry AMD...BHR Pharma LLC, of Herndon, Va., said the 1,000th patient has been enrolled in its SyNAPSe clinical trial, a global Phase III study evaluating the effectiveness of its intravenous progesterone infusion agent, BHR-100, to treat severe traumatic brain injury (TBI...BHR Pharma is sponsoring SyNAPSe with the intent to bring the first-ever approved TBI treatment to market -
Pharma: Clinic Roundup
Pfizer Inc., of New York, said the REMINDER trial of Inspra (eplerenone) showed statistically significant risk reductions in the primary composite efficacy endpoint, defined as time to first event of cardiovascular mortality, re-hospitalization or extended initial hospital stay due to diagnosis of heart failure (HF), sustained ventricular tachycardia or fibrillation, ejection fraction (EF) BioWorld Today | Tuesday, March 12, 2013
e-Therapeutics Raises $63M to Fund Solid Tumor Drug
Pharma doesn't want more questions than answers, so you can't do development on a shoestring or cut corners...BrainStorm Cell Therapeutics Inc., of New York, said it has signed a $250,000 common stock purchase agreement with an individual private investor
Clinic Roundup
BrainStorm Cell Therapeutics Inc., of New York, said the Israeli Ministry of Health fast-tracked the firm's Phase I/II amyotrophic lateral sclerosis safety study to a Phase IIa dose-escalating trial, which significantly expedites the clinical development program...Cerulean Pharma Inc., of Cambridge, Mass., said CRLX101 achieved the predefined gating criterion for advancement into the second stage of a Phase II trial in advanced ovarian cancer...The complete clinical study report for the interim
Clinic Roundup
Cerulean Pharma Inc., of Cambridge, Mass., said it dosed the first patient in a Phase II study of lead candidate CRLX101 in advanced gastric cancer...Dipexium Pharmaceuticals LLC, of New York, said it reached an agreement with the FDA on a special protocol assessment for an upcoming Phase III study testing Locilex (pexiganan acetate cream 1 percent), an antibiotic peptide formulated as a topical cream, in mild infections of diabetic foot ulcers...TG Therapeutics Inc., of New York, said the FDA cleared
HC Royalty Inks Hefty Deals to Propel Nuron and Raptor
As a small biotech with one foot in infectious disease and the other in neurology while having one hand in commercial products and the other in clinical development, "we have a unique strategy, and so far it's working well," Musunuri said...New York investment fund Platinum-Montaur Life Sciences LLC exercised Series W warrants to purchase 6 million shares of common stock in Navidea Biopharmaceuticals Inc., of Dublin, Ohio
Clinic Roundup
EyeGate Pharma Inc., of Waltham, Mass., said it enrolled the last patient in a 200-subject pivotal Phase III study of EGP-437 (dexamethasone phosphate ophthalmic solution) in patients with anterior uveitis...Transparency Life Sciences LLC, of New York, said the FDA cleared an investigational new drug application for lisinopril in multiple sclerosis
To 'Infinity' and Beyond: $150M to Propel PI3K Inhibitor IPI-145
Data also indicated rapid onset of activity, with clinical activity reported for 16 of 19 responders occurring within the first two cycles of treatment...OncoSec plans to use the proceeds to fund clinical trials and research and development and for other corporate purposes...The company plans to use the proceeds to fund research and development, clinical trials and for other corporate purposes.
Clinic Roundup
CellAct Pharma GmbH, of Dortmund, Germany, said its topoisomerase inhibitor CAP7...Intercept Pharmaceuticals Inc., of New York, completed patient enrollment in the FLINT Phase IIb trial of obeticholic acid (OCA) for adult nonalcoholic steatohepatitis
FLT3 Bid 'Astellas' Promising as Before: Ambit Raises $50M
At least a year shy of the next milestone payment from partner Astellas Pharma Inc., Ambit Biosciences Inc...Funds will be used for working capital and general corporate purposes, including the funding of its ongoing clinical trials...The net proceeds will be used for working capital and general corporate purposes, including the continued conduct of the Abili-T clinical study, Opexa's recently initiated Phase IIb trial of personalized T-cell therapy Tcelna in patients with secondary progressive
Clinic Roundup
TransTech Pharma Inc., of High Point, N.C., said data from a 399-patient study testing TTP488, a small-molecule drug targeting the receptor for advanced glycation endproducts, demonstrated evidence of slowing cognitive decline over 18 months in patients with mild to moderate Alzheimer's disease...The study was sponsored by New York-based Pfizer Inc
Cat on a Hot Twin Proof? After Cougar, Puma Roars
The clinical relevance of neratinib as a 'pan-HER' family inhibitor and it being irreversible is yet to be proven," the paper said...Funds will be used to support the clinical development of cancer drugs aldoxorubicin and tamibarotene and for general corporate purposes, which could include working capital, capital expenditures, R&D and commercial activities.
Pharma: Clinic Roundup
Bristol-Myers Squibb Co., of New York, and Pfizer Inc., also of New York, reported that the reductions in stroke or systemic embolism, major bleeding and mortality demonstrated with Eliquis (apixaban) compared to warfarin in the ARISTOTLE trial were consistent across a wide range of stroke and bleeding risk scores in patients with nonvalvular atrial fibrillation